仿生金属有机抗氧化剂眼滴用于角膜新血管化:可见光触发的CO释放用于微环境监管
Yuhang Cheng1,2, Hongjin Li1,2, Xingyuan Wei1,2
1Xiamen University Affiliated Xiamen Eye Center, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen 361102, China.
Nano letters
|July 16, 2025
概括
新型抗氧化剂眼滴在照明下释放一氧化碳 (CO) 气体,用于治疗角膜新血管化 (CNV). 这种创新疗法可以减少炎症并抑制血管生长,提供一种安全的CNV管理策略.
科学领域:
- 眼科医生 眼科 眼科
- 生物材料科学 生物材料科学
- 纳米医学是一种纳米医学.
背景情况:
- 眼睛表面容易发生氧化应激和炎症,导致角膜新血管化 (CNV).
- 目前对神经性肺炎的治疗方法往往存在局限性,需要新的治疗方法.
研究的目的:
- 开发和评估新型生物仿真抗氧化剂眼滴,用于治疗CNV.
- 调查光触发的一氧化碳 (CO) 气体释放纳米医药在控制角膜氧化应激和新血管化的有效性.
主要方法:
- 合成了一种纳米药物 (ZrMn/CO@ScFv) 使用联合组装的Mn-TCPP,Bpy-COOH,Zr(IV) 八水和Mn(CO) 5Br,涂有抗VEGFR2单链抗体的基因工程细胞膜囊泡 (ScFv).
- 以眼滴的形式使用纳米药物,利用其光敏性质在可见光下释放CO气体.
- 在CNV的背景下评估了氧化应激的抑制,和炎症的减少以及血管原因子 (CD31,VEGF) 的抑制.
主要成果:
- 这种纳米药物有效地抑制了氧化应激,局部和炎症.
- 治疗显著降低了血管新生因子CD31和VEGF的表达.
- 开发的眼滴证明了对角膜新血管化的有效治疗.
结论:
- 抗氧化剂和气体治疗的协同组合为控制心血管疾病提供了安全有效的策略.
- 光触发的CO释放纳米药物对治疗诸如CNV之类的眼睛表面疾病具有前景.
相关概念视频
01:28Angle Closure Glaucoma: Treatment
697
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
697
01:27Open Angle Glaucoma: Treatment
579
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
579